1 2	Initiation of Warfarin is associated with Decreased Mortality in Patients with Infective Endocarditis: A Population-Based Cohort Study
3 4 5 6 7	Teddy Tai Loy Lee ^{1,2} , Sunny Ching Long Chan ¹ , Oscar Hou In Chou MSc ^{2,3} , Sharen Lee MBChB ² , Jeffrey Shi Kai Chan MBChB MPH ² , Tong Liu MD PhD ⁴ , Carlin Chang MBChB MPhil ⁵ , Wing Tak Wong PhD ⁶ , Gregory Y. H. Lip MD ^{7,8} , Bernard Man Yung Cheung MBBChir PhD ³ , Abraham Ka-Chung Wai MBChB ¹ , Gary Tse MD PhD ^{4,9,10}
8	1. Department of Emergency Medicine, School of Clinical Medicine, The University of
9	Hong Kong, Hong Kong, China
10	2. Cardiovascular Analytics Group, China-UK Collaboration, Hong Kong, China
11	3. Division of Clinical Pharmacology, School of Clinical Medicine, The University of Hong Kong Hong Kong, Ching
12 13	Hong Kong Hong Kong, China 4 Tioniin Institute of Cardiology. The Second Hospital of Tioniin Medical University
15 14	4. Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
15	5. Division of Neurology, Department of Medicine, Queen Mary Hospital and The
16	University of Hong Kong Hong Kong, China
17	6. State Key Laboratory of Agrobiotechnology (CUHK), School of Life Sciences, The
18	Chinese University of Hong Kong, Hong Kong, China
19	7. Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool
20	John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United
21	Kingdom
22	8. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
23	9. Kent and Medway Medical School, University of Kent and Canterbury Christ Church
24	University, Canterbury, United Kingdom
25	10. School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong
26	Kong, China
27	
28	Correspondence to:
29	Dr. Abraham Ka-Chung Wai, MBChB, FRCEM, FRCP
30	Department of Emergency Medicine, School of Clinical Medicine, The University of Hong
31	Kong, Hong Kong, China
32	Email: <u>awai@hku.hk</u>
33	
24	Prof Corv Too MD DhD EDCD EEDU
34 35	Prof. Gary Tse, MD, PhD, FRCP, FFPH Kent and Medway Medical School, University of Kent and Canterbury Christ Church
36	University, Canterbury, United Kingdom
27	Tionin Institute of Cardiology The Second Hespitel of Tionin Medical University Tionin

- Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin 37
- 300211, China 38
- 39 School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong,
- China 40
- Email: gary.tse@kmms.ac.uk 41
- 42
- 43 Word count: 3617

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

44 Abstract

45 Importance: The use of warfarin as an anticoagulant to prevent thromboembolism in patients
46 with infective endocarditis (IE) remains controversial due to potentially increased bleeding
47 risks.

48 **Objective:** This study compared the risks of ischemic stroke, death and bleeding in patients

- 49 with IE with and without warfarin use.
- 50 **Design:** Prospective cohort study.

51 Setting: Population-based.

Participants: Patients aged 18 or older and diagnosed with IE in Hong Kong between January 1st 1997 and August 31st 2020 were included. Patients with use of any anticoagulant 30 days before IE diagnosis were excluded. Patients initiated on warfarin within 14 days of IE diagnosis and patients without warfarin use were matched for baseline characteristics using 1:1 propensity score matching.

Main outcomes and measures: Patients were followed up to 90 days for the outcomes of ischemic stroke, all-cause mortality, intracranial hemorrhage, and gastrointestinal bleeding. Cox regression was used to determine hazard ratios (HRs) [95% confidence intervals (CIs)] between treatment groups. Fine-Gray competing risk regression with all-cause mortality as the competing event was performed as a sensitivity analysis. In addition to 90-day analyses, landmark analyses were performed at 30 days of follow-up.

Results: The matched cohort consisted of 675 warfarin users (57.0% male, age 59±16 years)
and 675 warfarin non-users (53.5% male, age 61±19 years). From Cox regression, warfarin
users had a 50% decreased 90-day risk in all-cause mortality (HR: 0.50 [0.39-0.65]), without

⁵⁷ **Exposure:** Warfarin use within 14 days of IE diagnosis.

significantly different 90-day risks of ischemic stroke (HR: 1.04 [0.70-1.53]), intracranial
haemorrhage (HR: 1.25 [0.77-2.04]), and gastrointestinal bleeding (HR: 1.04 [0.60-1.78]).
Thirty-day landmark analysis showed similar results. Competing risk regression showed
significantly higher 30-day cumulative incidence of intracranial haemorrhage in warfarin users
(sub-HR: 3.34 [1.34-8.31]), but not at 90-day (sub-HR: 1.63 [0.95-2.81]). Results from FineGray regression were otherwise congruent with those from Cox regression.
Conclusions and relevance: In patients with IE, warfarin use initiated within 14 days of IE

74 diagnosis may be associated with significantly decreased risks of mortality but higher risks of

rs intracranial haemorrhage, with similar risks of ischemic stroke and gastrointestinal bleeding,

compared with non-use of warfarin with 14 days of IE diagnosis.

78 Key points

- **Question**: Is warfarin, initiated within 14 days of a diagnosis of infective endocarditis (IE),
 efficacious and safe?
- 81 Findings: In this propensity score-matched, population-based, prospective cohort study from
- 82 Hong Kong, warfarin use within 14 days of IE diagnosis was associated with a 50% decrease
- 83 in the risk of all-cause mortality, albeit with higher risk of intracranial haemorrhage, and
- 84 without significant differences in the risk of ischaemic stroke and gastrointestinal bleeding.
- 85 Meaning: In patients with IE, warfarin use within 14 days of diagnosis may have mortality
- 86 benefits, despite increased risks of intracranial haemorrhage.

88 Non-standard Abbreviations and Acronyms

- 89 ACE: Angiotensin-converting enzyme
- 90 **CDARS:** Clinical data analysis and reporting system
- 91 **CI:** Confidence interval
- 92 **DOAC:** Direct oral anticoagulant
- 93 HACEK: Hemophilus species, Aggregatibacter actinomycetemcomitans, Cardiobacterium
- 94 hominis, Eikenella corrodens, Kingella kingae
- 95 HR: Hazard ratio
- 96 H2RA: Histamine type 2 receptor antagonist
- 97 ICD-9: International Classification of Diseases, Ninth Revision
- 98 **INR:** International normalized ratio
- 99 **IE:** Infective endocarditis
- 100 **NSAID:** Nonsteroidal anti-inflammatory drug
- 101 **OR:** Odds ratio
- 102 **PPI:** Proton pump inhibitor
- 103 **SD:** Standard deviation
- 104 SHR: Sub-hazard ratio
- 105 **SMD:** Standardized mean difference
- 106 VR: Variance ratio
- 107

108 Introduction

Infective endocarditis (IE) is an acute infection of the cardiac endothelium, 109 characterized by adherence of platelets and fibrin to the endocardial wall in response to injury, 110 forming a vegetation inducing cardiac damage and development of thromboembolic 111 complications. Despite being a rare condition with an annual incidence of 3-10 cases per 112 100,000 people^{1,2}, IE is a challenging condition associated with a high mortality and morbidity, 113 with a reported mortality rate of 30% at 30 days³. Without proper treatment, further platelet 114 aggregation and microbial proliferation allows IE vegetations to grow in size⁴, subsequently 115 leading to increased risk of septic embolization ⁵. Ischemic stroke, a common and disabling 116 neurological complication caused by an embolized vegetation, has a prevalence of 16.9% ⁶ and 117 is a leading cause of death in IE 7,8 . 118

Though fibrin constitutes the main component in vegetations ^{9, 10}, the current 2015 119 European Society of Cardiology guidelines do not suggest IE per se as an indication for 120 initiating anticoagulation¹¹. However, preclinical studies have shown that anticoagulant use is 121 associated with reduced vegetation size, bacterial load, and inflammation in IE^{12, 13} and may 122 have a role in long-term IE prophylaxis ¹⁴. Indeed, the role of anticoagulation therapy in IE 123 management is highly controversial due to the associated bleeding risks. Warfarin is a Vitamin 124 K antagonist which inhibits Vitamin K epoxide production of clotting factors and has 125 previously been used to treat valvular vegetations and as prophylaxis against embolic stroke ¹⁵⁻ 126 ¹⁷. However, the benefits of prophylaxis must be balanced against bleeding risks, notably 127 intracranial hemorrhage ¹⁸. 128

Current data on the efficacy and safety of warfarin therapy in IE are limited, and published clinical studies often have a small numbers of patients. Owing to the lack of evidence, surgical treatment and antibiotics remain the preferred option for reducing the risk of ischemic

stroke. Therefore, the present study examined the efficacy in terms of stroke risk reduction,
and safety in terms of bleeding risks of warfarin use in a large population-based cohort of
patients with IE.

135

136 Methods

This study was been approved by The Chinese University of Hong Kong-New 137 Territories East Cluster Clinical Research Ethics Committee and The University of Hong 138 139 Kong/Hospital Authority Hong Kong West Cluster Institutional Review Board. The need for informed consent was waived owing to the retrospective use of deidentified patient data in this 140 study. Patient data was obtained through the Clinical Data Analysis and Reporting System 141 (CDARS), a territory-wide electronic healthcare database managed by the Hong Kong Hospital 142 Authority, which serves an estimated 90% of the population in Hong Kong. CDARS has 143 previously been used extensively to conduct large population-based studies ^{19, 20}, including 144 those on anticoagulation use ^{21, 22}. 145

146 Study Cohort

All patients aged 18 or above with a diagnosis of IE who attended any public hospitals between January 1st, 1997 to August 31st, 2020 were identified from CDARS. The date of first diagnosis of IE was defined as the index date. Patients who received warfarin prescriptions within 14 days since the index date were considered warfarin users. To select new users only, patients who received warfarin or other anticoagulant medications (rivaroxaban, dabigatran, apixaban, edoxaban, enoxaparin, fondaparinux or heparin) within an entry period 30 days prior to the index date were excluded.

154 *Outcomes*

To study the efficacy and safety of warfarin use, study outcomes included 90-day risks of embolic stroke and all-cause mortality (efficacy), and intracranial hemorrhage and gastrointestinal bleeding (safety). An *a priori* landmark analysis was done at 30 days to compare the 30-day risks. Details of International Classification of Diseases, Ninth Revision (ICD-9) codes used to define outcomes are described in **Supplementary Table 1**. Outcomes were followed up until the occurrence of outcome, death, or until 90 days after IE diagnosis, whichever earlier.

162 *Covariates*

We traced patient records on CDARS prior to the index date and collected patient 163 information including age at index date, sex, comorbidities (hypertension, atrial fibrillation, 164 165 heart failure, diabetes mellitus, ischemic heart disease, chronic kidney disease, vascular 166 disease), history of valvular replacement, and recent medication use, including drugs related to bleeding risk (ACE inhibitors, angiotensin receptor blockers, beta blockers, nonsteroidal anti-167 168 inflammatory drugs [NSAIDs], histamine type 2 receptor antagonists [H2RAs], proton pump inhibitors [PPIs], selective serotonin reuptake inhibitors [SSRIs]), and pathogens identified 169 from blood culture (staphylococci, streptococci, enterococci, HACEK group) taken during IE 170 admission. We also traced the number of patients who received direct oral anticoagulants 171 (DOACs), heparin (fondaparinux, enoxaparin, heparin), and cardiac surgery (ICD-9-CM 172 173 Procedure codes 35-39) within 14 days since the index date. ICD-9 codes used to identify comorbidities are described in Supplementary Table 1. 174

175 Statistical Analysis

This study tested the hypothesis that when compared to non-usage, warfarin usage is associated with different risks of efficacy and safety study outcomes of ischemic stroke, allcause mortality, intracranial hemorrhage and gastrointestinal bleeding. To account for

differences between groups in baseline characteristics due to a lack of randomization, we used 179 propensity score matching on a 1:1 ratio using the nearest-neighbour matching algorithm to 180 match warfarin users with non-users by the aforementioned covariates. A caliper width of 0.2 181 was chosen as it is considered optimal for propensity score matching ²³. Standardized mean 182 differences (SMD), the differences in means over the pooled standard deviation (SD) assessed 183 balance of categorical covariates; the variance ratio (VR), which is the ratio of variance 184 185 between the treatment and control groups assessed balance of both categorical and continuous covariates. Characteristics with an SMD of <0.1 or VR between the range of 0.5 and 2.0 were 186 187 considered balanced. Descriptive statistics were expressed as mean \pm SD and count (percentage [%]) as appropriate. 188

Result estimates were expressed in terms of hazard ratios (HRs) with 95% confidence 189 intervals (CIs) using a univariate Cox proportional hazards model. The proportional hazards 190 assumption of the model was tested by performing the Schoenfeld proportionality test; the 191 results indicated that the assumption was met. Kaplan-Meier curves were plotted against the 192 time-to-event, beginning from the date of IE diagnosis stratified by either warfarin use or no 193 warfarin use for the main results, and beginning from the date of warfarin initiation and 194 stratified by either early or late initiation of warfarin for analysis of warfarin timing. The log-195 rank test was performed to investigate the statistical significance of differences in survival 196 197 between comparator groups.

An *a priori* subgroup analysis was performed: 90-day risks of the efficacy outcomes in patients who were initiated on warfarin early (\leq 7 days) were compared to those with late initiation (within 8 to 14 days) to explore the effect of initiation timing within warfarin users; in this analysis, the start date of follow-up was defined as the date of warfarin initiation instead of date of IE diagnosis. As there were substantial imbalances between treatment arms in the respective proportions of patients who received cardiac surgery and heparin within 14 days of

the index day, two *post hoc* subgroup analyses were added, where patients who received 204 cardiac surgery and heparin were excluded separately. Furthermore, two *a priori* sensitivity 205 analyses were conducted. First, the period in which warfarin was initiated was restricted from 206 within 14 days to within 7 days of the index date. Second, a competing risk regression was 207 performed for ischaemic stroke, intracranial haemorrhage, and gastrointestinal bleeding using 208 the Fine and Gray sub-distribution model, with all-cause mortality as the competing event, and 209 210 with sub-hazard ratios (SHRs) and the corresponding 95% CIs as summary statistics. Aalen-Johansen cause-specific cumulative incidence curves were additionally plotted for these 211 212 outcomes to account for competing risks.

All analyses were conducted using R (version 1.4.1717) or Stata (version 16.1). All pvalues were two-tailed and considered statistically significant when P < 0.05.

215

216 **Results**

217 *Patient characteristics*

The patient flow is shown in **Figure 1**. In total, 7,054 patients with a diagnosis of IE were identified from CDARS. After excluding patients with previous anticoagulant use, under 18 years old, and those with use of warfarin after 14 days since IE diagnosis, the study cohort consisted of 5,477 patients, where 734 patients received warfarin (56.7% male, mean baseline age: 60 ± 16 years old) and 4743 without warfarin use (66.5% male, mean baseline age: 58 ± 20 years old). All patients completed 90-day follow up or had 90-day mortality.

After 1:1 propensity score matching, the final study cohort consisted of 675 warfarin users and 675 without warfarin use. The baseline characteristics of the study population are shown in **Table 1**. A Love plot summarizing covariate balance before and after propensity score matching is shown in **Supplementary Figure 1**. All SMD values were <0.1 and VR

values within 0.5-2.0, indicating good balance between warfarin users and those without
warfarin use; the only exception being age, which had a SMD of 0.13. After matching, 13
(1.9%) warfarin users and 23 (3.4%) patients without warfarin use received DOACs, while 435
(64.4%) warfarin users 68 (10.1%) patients without warfarin use received heparin. 162 (24.0%)
warfarin users compared to 59 (8.7%) patients without warfarin use received cardiac surgery
within 14 days of IE diagnosis.

The ten most common causes of death were described in **Supplementary Table 2**. The 234 most common causes of death in warfarin users were IE (7.0%), followed by pneumonia (2.2%), 235 sepsis (1.2%), heart failure (0.9%), and rheumatic heart disease (0.6%); while in patients 236 without warfarin use, the most common causes of death were IE (2.5%), followed by 237 pneumonia (1.2%), stroke (0.9%), rheumatic heart disease (0.6%), and intracranial hemorrhage 238 (0.6%). 2 (0.3%) patients without warfarin use and 6 (0.9%) patients with warfarin use died of 239 stroke, while 6 (0.8%) patients without warfarin use and 7 (1.0%) patients with warfarin use 240 died of intracranial, intracerebral or subarachnoid hemorrhage (Supplementary Table 3). 241

242 Main 90- and 30-day analytic results

243 The main analytic results are presented in **Table 2**, and Kaplan-Meier plots are shown in **Figure 2**. While warfarin use was not associated with a significantly different 90-day risk 244 of ischemic stroke (HR: 1.04 [95% CI, 0.70-1.53], log-rank p=0.86), it was associated with a 245 246 50% decrease in the 90-day risk of all-cause mortality (HR: 0.50 [0.39-0.65], log-rank p<0.0001). For the safety outcomes, warfarin use was not associated with significantly 247 different 90-day risks of gastrointestinal bleeding (HR 1.04 [0.60-1.78], log-rank p=0.90), 248 249 although a nonsignificant trend for intracranial hemorrhage (HR: 1.25 [0.77-2.04]; log-rank 250 p=0.37) may be present.

Results of the 30-day landmark analysis for ischemic stroke (HR: 0.87 [0.53-1.43]), allcause mortality (HR: 0.41 [0.28-0.58]), intracranial hemorrhage (HR: 1.57 [0.80-3.07]) and gastrointestinal bleeding (HR: 0.86 [0.41-1.81]) were consistent with those of the main, 90-day analysis.

255 Subgroup analysis

Results of subgroup analyses are shown in Table 2 as well. In the *a priori* subgroup
analysis exploring the effects of the timing of warfarin initiation, warfarin initiation between
8-14 days of IE diagnosis (delayed use; N=152) was not associated with significantly different
90-day risks of ischemic stroke (HR: 1.53 [0.82-2.86]) or all-cause mortality (HR: 1.29 [0.782.14]) compared with early use (warfarin initiation within the seven days of IE diagnosis;
N=523; Figure 3). Landmark analysis at 30 days showed consistent results (Supplementary
Table 4).

In the first *post hoc* subgroup analysis excluding patients who received heparin within 263 14 days of IE diagnosis, warfarin use was associated with significantly lower 90-day risk of 264 all-cause mortality (HR: 0.59 [0.40-0.86]), but also significantly higher 90-day risk of 265 266 intracranial haemorrhage (HR: 2.56 [1.13-5.81]; Supplementary Figure 2); the 90-day risk of intracranial haemorrhage and gastrointestinal bleeding were not significantly different between 267 treatment arms. Landmark analysis at 30 days showed largely consistent results, except for the 268 269 nonsignificant trend in the 30-day risk of intracranial haemorrhage between treatment arms 270 (HR: 2.54 [0.98-6.54]).

In the second *post hoc* subgroup analysis excluding patients who received cardiac surgery within 14 days of IE diagnosis, warfarin use was again associated with significantly lower 90-day risk of all-cause mortality (HR: 0.47 [0.35-0.64]), but also significantly higher 90-day risk of intracranial haemorrhage (HR: 1.89 [1.01-3.53]; **Supplementary Figure 3**); the

90-day risk of intracranial haemorrhage and gastrointestinal bleeding were not significantly
different between treatment arms. Landmark analysis at 30 days showed largely consistent
results, except the 30-day risk of intracranial haemorrhage was not significantly different
between treatment arms (HR: 1.71 [0.78-3.73]).

279 Sensitivity analysis

Results of sensitivity analyses were summarized in Table 3. When only patients with
warfarin use within seven days of IE diagnosis were included in the warfarin arm (N=523),
warfarin use was associated with significantly lower 90-day risk of all-cause mortality (HR:
0.51 [0.38-0.67]), but not significantly different 90-day risks of ischemic stroke (HR: 0.81
[0.54-1.23]), intracranial hemorrhage (HR: 0.75 [0.45-1.26]), nor gastrointestinal bleeding (HR:
0.56 [0.30-1.03]).

In the Fine and Gray competing risk regression with all-cause mortality as competing events, warfarin users had significantly higher 30-day cumulative incidence of intracranial haemorrhage (SHR 3.34 [1.34-8.31]; **Supplementary Figure 4**), but the 90-day cumulative incidence was not significantly different between groups (SHR 1.63 [0.95-2.81]). The cumulative incidences of iscahemic stroke (**Supplementary Figure 5**) and gastrointestinal bleeding (**Supplementary Figure 6**) were not significantly different between groups at both 30 and 90 days.

293

294 Discussion

To the best of the authors' knowledge, this is the first population-based study on warfarin use in IE patients. In this study, warfarin use in patients with IE was associated with a significantly lower risk of mortality, without significantly different risks of ischemic stroke.

However, warfarin use may be associated with significantly higher risk of intracranialhaemorrhage, despite a lack of significant differences in the risk of other bleeding events.

The most important finding of this study was that in patients with IE, warfarin use was 300 associated with lower mortality risks at both 30 and 90 days. The reduction of clotting factors 301 and reduced platelet aggregation through warfarin use may slow the local proliferation of 302 303 vegetation, reducing valvular destruction and the extent of the infection, leading to improved prognosis. Clinically, these properties of warfarin are most leveraged for ischaemic stroke 304 prevention. In this study, however, the mortality benefit observed for warfarin use was clearly 305 not driven by ischaemic stroke risk reduction, as warfarin use was not associated with 306 significantly different risk of ischaemic stroke. This contrasts with two studies focused on left-307 sided staphylococcus aureus IE, where anticoagulation was found to reduce stroke risk ^{24, 25}. 308 For example, Rasmussen and colleagues described in a study of 175 IE patients that 309 anticoagulant use, defined as use of either coumadin or high-dose low molecular weight 310 heparin, was associated with a fourfold decrease in stroke risk (adjusted odds ratio [aOR]: 0.27), 311 but most patients who received anticoagulants had prosthetic valves (73%) compared to those 312 without anticoagulant use (8%)²⁴. In another cohort study of 587 IE episodes, warfarin use 313 314 was associated with a lower risk of cerebrovascular complications (aOR: 0.26 [95% CI, 0.07-0.94]), where 38% of patients with warfarin use and 12% patients without warfarin use had 315 atrial fibrillation on admission ²⁵. Nonetheless, both studies included patients who already had 316 continuous use of anticoagulants prior to IE admission. As patients already on treatment may 317 have stably reached the therapeutic international normalized ratio (INR) range, the baseline 318 risk for stroke of the anticoagulant group may be lower at the time of IE diagnosis. Instead, to 319 320 ensure a new-user design, we excluded patients with prior use of any anticoagulant within 30 days before IE diagnosis, and balanced the coagulability status of treatment groups by matching 321

with medications that influence coagulability, which may explain the lack of significant benefitamong new users in reducing ischemic stroke risk compared to previous studies.

The mortality benefit may be driven by a reduction in the size of vegetation, as 324 suggested by previous studies ^{15, 24}. As echocardiography data were not available, this could 325 not be verified in our study. It is also unclear whether effects on the size of vegetation was 326 affected by the causative organism. Another potential driver of the observed associations may 327 be differences in the risks of thromboembolic complications such as septic pulmonary 328 embolism²⁶. Septic pulmonary emboli pose high risk to patients as it can cause subsequent 329 respiratory failure requiring mechanical ventilation and prolonging hospital stay ²⁷. Though 330 anticoagulation has a well-established role for prophylaxis of noninfective pulmonary 331 embolism²⁸, it is not used for active treatment of septic pulmonary emboli due to the increased 332 bleeding risk in area of the infected emboli ⁵. Nevertheless, treatment of septic pulmonary 333 emboli using anticoagulation has been described in small cohort studies ^{29, 30}. Further research 334 on the potential effects of warfarin on vegetation size and thromboembolic complications and 335 the prognostic implications of any such effect is warranted. 336

The use of antiplatelet therapy in reducing mortality or embolic risk in IE is similarly 337 controversial. In a retrospective cohort study of 600 IE patients, patients with prior use of 338 339 aspirin, dipyridamole, clopidogrel or ticlopidine had a lower risk of stroke compared to control, but not significantly different mortality ³¹. In a randomized controlled trial of 115 IE patients, 340 treatment with aspirin 325mg/day did not significantly reduce the risk of embolic stroke nor 341 in-hospital mortality, instead increasing the risk of bleeding ³²; also, this trial excluded patients 342 with previous antiplatelet use, similar to our study. Interestingly, low-dose aspirin, compared 343 to high-dose aspirin, was more effective at reducing bacterial density and vegetation weight ³³. 344 Furthermore, a recent cohort study involving 34 IE patients compared long term use of 345 antiplatelets or anticoagulants and patients without the use of either medication class. Embolic 346

events occurred in 30% of patients receiving treatment and 7.1% not receiving treatment, with 347 similar mortality risk between both groups ³⁴. The study found a lower number of bleeding 348 events in the group without antiplatelet/anticoagulant use, in agreement with the subgroup 349 analysis in the current study where patients who received heparin within 14 days of IE 350 diagnosis were excluded. In local clinical practice, the vast majority of admitted IE patients are 351 started on warfarin instead of DOACs due to valvular nature of the disease; therefore, it was 352 353 not possible to conduct separate analyses investigating DOAC use on the study outcomes. It remains to be elucidated whether or not DOACs are similarly associated with a decreased risk 354 355 of mortality in the context of IE. Overall, there is a lack of consensus on the role of antithrombotics in general in the management of IE, be it anticoagulants or antiplatelets, and 356 the use of systemic antibiotics remains the preferred strategy to reduce the risks of mortality 357 and septic embolization ^{11, 35, 36}. 358

Previous evidence on anticoagulation in IE is mostly based on case reports or non-359 representative observational studies, which were limited by small sample sizes and sampling 360 bias. Nonetheless, a placebo-controlled trial on this study topic is difficult to organize given 361 the potential risk of bleeding in warfarin use. The present study attempted to minimize 362 indication bias for warfarin prescription by propensity score matching with potential 363 confounders such as prosthetic valve replacement, CHA2DS2-VASc score and atrial fibrillation. 364 365 The population-based nature of the study also meant that the results are widely generalizable, at least to other developed Asian cities. Moreover, we performed a number of subgroup and 366 sensitivity analyses to ensure robustness of our analyses, observing mostly consistent findings 367 in patients who did not receive cardiac surgery or heparin, and in both patients with early and 368 late warfarin use. The subgroup analysis of patients who did not receive cardiac surgery was 369 especially important, as the implantation of mechanical prosthetic valves could have been the 370 primary indication of warfarin in some patients. By demonstrating consistent results in patients 371

who did not receive cardiac surgery, the associations between warfarin use and lower mortality 372 risk was likely to be explained by factors other than warfarin being a surrogate for surgical 373 treatment. Nonetheless, it must be stressed that clinicians should be aware that warfarin use 374 was likely associated with higher risk of intracranial haemorrhage, as shown in the two post 375 *hoc* subgroup analyses of patients and in the competing risk regression. Although mortality 376 benefit was shown despite such detrimental associations with bleeding risks, more work is 377 378 needed to carefully delineate the risk-benefit balance in using warfarin in patients with IE, especially with the consideration of morbidity in addition to mortality, before more definitive 379 380 recommendations can be made for clinical practice.

381

382 *Limitations*

The present study has several limitations. First, there was incomplete baseline INR data 383 of patients within the treatment group and the coagulability status of study patients before 384 initiation on warfarin is unknown. This was addressed by excluding patients with use of 385 anticoagulants within 30 days before IE diagnosis in both treatment groups. Second, this study 386 387 did not account for the treatment duration, interruption or discontinuation of therapy in warfarin users, which may influence ischemic stroke or mortality risk. Major bleeding events such as 388 intracranial hemorrhage and gastrointestinal bleeding may prompt interruption of anticoagulant 389 therapy ¹¹, which, if abrupt, may lead to a sharp drop in INR ³⁷, in turn increasing the risk of 390 ischemic stroke. Third, this was an observational study; owing to limitations of the CDARS 391 database, echocardiographic findings such as the size of vegetation, valvular destruction, and 392 393 perivalvar abscesses were not coded in the system and therefore could not be explored. Fourth, although a number of baseline characteristics were used for propensity score matching, the 394 observational nature of this study meant that unobserved and residual confounders cannot be 395

396	completely eliminated. Nonetheless, we believe the baseline characteristics considered should
397	be pragmatically sufficient as a representation of the overall comorbid status of the included
398	patients. Lastly, as all diagnoses and outcomes were ascertained using ICD codes, miscoding
399	may be possible. Nonetheless, CDARS and the linked Hong Kong Death Registry have been
400	used extensively in peer-reviewed studies ³⁸⁻⁴⁰ , and all coding were performed by clinicians
401	independent of the authors.
402	
403	Conclusions
404	In patients with IE, warfarin use may be associated with decreased risks of mortality
405	compared with non-use of warfarin, with a non-significant difference in the risk of ischaemic
406	stroke and a higher risk of intracranial haemorrhage. Larger studies are warranted to confirm
407	these findings and delineate the underlying mechanisms.
408	
409	
410	Acknowledgements: None.
411	Sources of Funding: None.
412	Disclosures: None.
413	
414 415 416	Supplemental Material Tables S1-S3 Figures S1-S6

417 **References**

418	1.	Rajani R, Klein JL. Infective endocarditis: A contemporary update. Clin Med
419		(Lond). 2020;20:31-35
420	2.	Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le Moing V, et al. Temporal
421		trends in infective endocarditis in the context of prophylaxis guideline
422		modifications: Three successive population-based surveys. J Am Coll Cardiol.
423		2012;59:1968-1976
424	3.	Mostaghim AS, Lo HYA, Khardori N. A retrospective epidemiologic study to
425		define risk factors, microbiology, and clinical outcomes of infective endocarditis
426		in a large tertiary-care teaching hospital. SAGE Open Med.
427		2017;5:2050312117741772
428	4.	Hu W, Wang X, Su G. Infective endocarditis complicated by embolic events:
429		Pathogenesis and predictors. Clin Cardiol. 2021;44:307-315
430	5.	Mohananey D, Mohadjer A, Pettersson G, Navia J, Gordon S, Shrestha N, et al.
431		Association of vegetation size with embolic risk in patients with infective
432		endocarditis: A systematic review and meta-analysis. JAMA Intern Med.
433		2018;178:502-510
434	6.	Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG, Jr., Bayer AS, et al.
435		Clinical presentation, etiology, and outcome of infective endocarditis in the 21st
436		century: The international collaboration on endocarditis-prospective cohort study.
437		Arch Intern Med. 2009;169:463-473
438	7.	Garcia-Cabrera E, Fernandez-Hidalgo N, Almirante B, Ivanova-Georgieva R,
439		Noureddine M, Plata A, et al. Neurological complications of infective
440		endocarditis: Risk factors, outcome, and impact of cardiac surgery: A multicenter
441		observational study. Circulation. 2013;127:2272-2284

442	8.	Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P.
443		Neurologic manifestations of infective endocarditis: A 17-year experience in a
444		teaching hospital in finland. Arch Intern Med. 2000;160:2781-2787
445	9.	Thiene G, Basso C. Pathology and pathogenesis of infective endocarditis in native
446		heart valves. Cardiovasc Pathol. 2006;15:256-263
447	10.	Holland TL, Baddour LM, Bayer AS, Hoen B, Miro JM, Fowler VG, Jr. Infective
448		endocarditis. Nat Rev Dis Primers. 2016;2:16059
449	11.	Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al.
450		2015 esc guidelines for the management of infective endocarditis: The task force
451		for the management of infective endocarditis of the european society of
452		cardiology (esc). Endorsed by: European association for cardio-thoracic surgery
453		(eacts), the european association of nuclear medicine (eanm). Eur Heart J.
454		2015;36:3075-3128
455	12.	Lerche CJ, Christophersen LJ, Goetze JP, Nielsen PR, Thomsen K, Enevold C, et
456		al. Adjunctive dabigatran therapy improves outcome of experimental left-sided
457		staphylococcus aureus endocarditis. PLoS One. 2019;14:e0215333
458	13.	Hook EW, 3rd, Sande MA. Role of the vegetation in experimental streptococcus
459		viridans endocarditis. Infect Immun. 1974;10:1433-1438
460	14.	Veloso TR, Que YA, Chaouch A, Giddey M, Vouillamoz J, Rousson V, et al.
461		Prophylaxis of experimental endocarditis with antiplatelet and antithrombin
462		agents: A role for long-term prevention of infective endocarditis in humans? J
463		Infect Dis. 2015;211:72-79
464	15.	Slivka AP, Agriesti JE, Orsinelli DA. Natural history of nonbacterial thrombotic
465		endocarditis treated with warfarin. Int J Stroke. 2021;16:519-525

466	16.	Lee SJ, Oh SS, Lim DS, Hong SK, Choi RK, Park JS. Usefulness of anticoagulant
467		therapy in the prevention of embolic complications in patients with acute infective
468		endocarditis. Biomed Res Int. 2014;2014:254187
469	17.	Sawant AC, Kumar A, McCray W, Tetewsky S, Parone L, Sridhara S, et al.
470		Superior safety of direct oral anticoagulants compared to warfarin in patients with
471		atrial fibrillation and underlying cancer: A national veterans affairs database
472		study. J Geriatr Cardiol. 2019;16:706-709
473	18.	Salaun E, Touil A, Hubert S, Casalta JP, Gouriet F, Robinet-Borgomano E, et al.
474		Intracranial haemorrhage in infective endocarditis. Arch Cardiovasc Dis.
475		2018;111:712-721
476	19.	Wai AK, Chan CY, Cheung AW, Wang K, Chan SC, Lee TT, et al. Association of
477		molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital
478		admissions and related avoidable healthcare system cost among high-risk patients
479		with mild to moderate covid-19. Lancet Reg Health West Pac. 2023;30:100602
480	20.	Lee TTL, Hui JMH, Lee YHA, Satti DI, Shum YKL, Kiu PTH, et al. Sulfonylurea
481		is associated with higher risks of ventricular arrhythmia or sudden cardiac death
482		compared with metformin: A population-based cohort study. J Am Heart Assoc.
483		2022;11:e026289
484	21.	Zhou J, Lee S, Liu X, Iltaf Satti D, Tai Loy Lee T, Hou In Chou O, et al. Hip
485		fractures risks in edoxaban versus warfarin users: A propensity score-matched
486		population-based cohort study with competing risk analyses. Bone.
487		2022;156:116303
488	22.	Zhou J, Leung KSK, Kong D, Lee S, Liu T, Wai AKC, et al. Low rates of liver
489		injury in edoxaban users: Evidence from a territory-wide observational cohort
490		study. Clin Cardiol. 2021;44:886-889

491	23.	Austin PC. Optimal caliper widths for propensity-score matching when estimating
492		differences in means and differences in proportions in observational studies.
493		Pharm Stat. 2011;10:150-161
494	24.	Snygg-Martin U, Rasmussen RV, Hassager C, Bruun NE, Andersson R, Olaison
495		L. Warfarin therapy and incidence of cerebrovascular complications in left-sided
496		native valve endocarditis. Eur J Clin Microbiol Infect Dis. 2011;30:151-157
497	25.	Rasmussen RV, Snygg-Martin U, Olaison L, Buchholtz K, Larsen CT, Hassager
498		C, et al. Major cerebral events in staphylococcus aureus infective endocarditis: Is
499		anticoagulant therapy safe? Cardiology. 2009;114:284-291
500	26.	Galzerano D, Pergola V, Kinsara AJ, Vriz O, Elmahi I, Al Sergani A, et al. Right-
501		sided infective endocarditis and pulmonary embolism: A multicenter study.
502		Monaldi Arch Chest Dis. 2022;92
503	27.	Elsaghir H, Al Khalili Y. Septic emboli. Statpearls. Treasure Island (FL); 2022.
504	28.	Freund Y, Cohen-Aubart F, Bloom B. Acute pulmonary embolism: A review.
505		JAMA. 2022;328:1336-1345
506	29.	Song XY, Li S, Cao J, Xu K, Huang H, Xu ZJ. Cardiac septic pulmonary
507		embolism: A retrospective analysis of 20 cases in a chinese population. Medicine
508		(Baltimore). 2016;95:e3846
509	30.	Goswami U, Brenes JA, Punjabi GV, LeClaire MM, Williams DN. Associations
510		and outcomes of septic pulmonary embolism. Open Respir Med J. 2014;8:28-33
511	31.	Anavekar NS, Tleyjeh IM, Anavekar NS, Mirzoyev Z, Steckelberg JM, Haddad
512		C, et al. Impact of prior antiplatelet therapy on risk of embolism in infective

513 endocarditis. *Clin Infect Dis.* 2007;44:1180-1186

514	32.	Chan KL, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek MA, et al. A
514	52.	Chan KL, Duneshn JO, Cujec B, Sannippo AJ, Jue J, Turek MA, et al. A
515		randomized trial of aspirin on the risk of embolic events in patients with infective
516		endocarditis. J Am Coll Cardiol. 2003;42:775-780
517	33.	Nicolau DP, Freeman CD, Nightingale CH, Quintiliani R, Coe CJ, Maderazo EG,
518		et al. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve
519		endocarditis. Infect Immun. 1993;61:1593-1595
520	34.	Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, et al. The
521		relationship between the initiation of antimicrobial therapy and the incidence of
522		stroke in infective endocarditis: An analysis from the ice prospective cohort study
523		(ice-pcs). Am Heart J. 2007;154:1086-1094
524	35.	Pathickal SM, Park TE, Sharma R. Clinical outcomes associated with the use of
525		anticoagulant and antiplatelet agents in patients undergoing treatment for infective
526		endocarditis: A pilot study. Clin Ther. 2020;42:1828-1838
527	36.	Davenport J, Hart RG. Prosthetic valve endocarditis 1976-1987. Antibiotics,
528		anticoagulation, and stroke. Stroke. 1990;21:993-999
529	37.	White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation
530		of warfarin therapy: Changes in the international normalized ratio. Ann Intern
531		Med. 1995;122:40-42
532	38.	Chan JSK, Lakhani I, Lee TTL, Chou OHI, Lee YHA, Cheung YM, Yeung HW,
533		Tang P, Ng K, Dee EC, Liu T, Wong WT, Tse G, Leung FP. Cardiovascular
534		outcomes and hospitalizations in Asian patients receiving immune checkpoint
535		inhibitors: a population-based study. Curr Probl Cardiol. 2023; 48(1): 101380.
536	39.	Li X, Chan JSK, Guan B, Peng S, Wu X, Lu X, Zhou J, Hui JMH, Lee YHA, Satti
537		DI, Tsang SL, Wu S, Chen S, Tse G, Liu S. Triglyceride-glucose index and the

538		risk of heart failure: evidence from two large cohorts and a Mendelian	
539		randomization analysis. Cardiovasc Diabetol. 2022; 21(1): 229.	
540	40. Lee YHA, Zhou J, Hui JMH, Liu X, Lee TTL, Hui K, Chan JSK, Wai AKO		
541		Wong WT, Liu T, Ng K, Lee S, Dee EC, Zhang Q, Tse G. Risk of new-onset	
542		prostate cancer for metformin versus sulphonylurea use in type 2 diabetes	
543		mellitus: a propensity score-matched study. J Natl Compr Cancer Netw. 2022;	
544		20(6): 674-682.e15.	

Figure 1: Study flow chart 546




Table 1: Characteristics of patients with infective endocarditis before and after 1:1 548

propensity score matching 549

Characteristics	Before matching		After matching			
	Warfarin use (N=734)	No warfarin use (N=4743)	Warfarin use (N=675)	No warfarin use (N=675)	SMD	VR
Demographics			1			
Male, N (%)	416 (56.7)	3156 (66.5)	385 (57.0)	361 (53.5)	0.04	-
Baseline age, years	59.63±15.89	58.12±19.64	59.36±16.25	61.45±18.74	0.13	0.75
Comorbidities	1					
Charlson Comorbidity Index	2.44±2.27	2.08±2.39	2.37±2.29	2.51±2.38	0.06	0.93
Hypertension, N (%)	137 (18.7)	828 (17.5)	126 (18.7)	137 (20.3)	0.02	-
Atrial fibrillation, N (%)	253 (34.5)	329 (6.9)	206 (30.5)	213 (31.6)	0.01	-
Heart failure, N(%)	229 (31.2)	522 (11.0)	187 (27.7)	202 (29.9)	0.02	-
Diabetes mellitus, N (%)	83 (11.3)	545 (11.5)	78 (11.6)	85 (12.6)	0.01	-
Intracranial hemorrhage, N (%)	25 (3.4)	108 (2.3)	21 (3.1)	24 (3.6)	< 0.01	-
Chronic kidney disease, N (%)	28 (3.8)	295 (6.2)	28 (4.1)	25 (3.7)	< 0.01	-
Vascular disease, N (%)	8 (1.1)	36 (0.8)	6 (0.9)	7 (1.0)	<0.01 0.02	-
Valvular replacement, N (%)	107 (14.6)	43 (0.9)	52 (7.7)	39 (5.8)	0.02	-
Medications			1			
ACE inhibitors, N (%)	151 (20.6)	473 (10.0)	130 (19.3)	147 (21.8)	0.02	-
Angiotensin receptor blockers, N (%)	38 (5.2)	124 (2.6)	33 (4.9)	32 (4.7)	<0.01	-
Beta blockers, N (%)	149 (20.3)	510 (10.8)	132 (19.6)	135 (20.0)	< 0.01	-
NSAIDs, N (%)	168 (22.9)	847 (17.9)	157 (23.3)	170 (25.2)	0.02	-
H2 receptor antagonists, N (%)	147 (20.0)	664 (14.0)	131 (19.4)	138 (20.4)	0.01	-
Proton pump inhibitors, N (%)	136 (18.5)	600 (12.7)	116 (17.2)	118 (17.5)	<0.01	-
Selective serotonin reuptake inhibitors, N (%)	8 (1.1)	47 (1.0)	8 (1.2)	6 (0.9)	<0.01	-
Blood culture results						
Staphylococci, N (%)	87 (11.9)	1023 (21.6)	73 (10.8)	69 (10.2)	< 0.01	-
Streptococci, N (%)	68 (9.3)	681 (14.4)	58 (8.6)	52 (7.7)	< 0.01	-
Enterococci, N (%)	12 (1.6)	112 (2.4)	8 (1.2)	11 (1.6)	< 0.01	-
HACEK group, N (%)	1 (0.1)	33 (0.7)	1 (0.1)	3 (0.4)	< 0.01	-
Outcomes						
Ischemic stroke, N (%)	57 (7.8)	314 (6.6)	52 (7.7)	50 (7.4)	-	-
All-cause mortality, N (%)	93 (12.7)	1246 (26.3)	83 (12.3)	193 (28.6)	-	-

Intracranial	39 (5.3)	184 (3.9)	36 (5.3)	29 (4.3)	-	-
hemorrhage, N (%)						
Gastrointestinal	30 (4.1)	146 (3.1)	27 (4.0)	26 (3.9)	-	-
bleeding, N (%)						
Treatments received w	ithin 14 days a	fter IE diagnosi	is			
Direct oral	13 (1.8)	47 (1.0)	13 (1.9)	23 (3.4)	-	-
anticoagulants, N (%)						
Heparin, N (%)	466 (63.5)	368 (7.8)	435 (64.4)	68 (10.1)	-	-
Cardiac surgery, N	171 (23.3)	453 (9.6)	162 (24.0)	59 (8.7)	-	-
(%)	. ,	. /				

551 Continuous variables were expressed as mean ± standard deviation. SMD and VR were only displayed for

552 variables considered in propensity score matching. SMD <0.1 / VR >0.5 & 2.0 indicated good balance in 553 matching.

554 ACE, Angiotensin-converting enzyme; IE: Infective endocarditis; NSAID: Nonsteroidal anti-inflammatory

555 drugs; SMD: Standardized mean difference; VR: Variance ratio.

Patient group	Outcomes	30-day risk Hazard ratio (95% CI)	90-day risk Hazard ratio (95% CI) 558
	Ischemic stroke	0.87 (0.53-1.43)	1.04 (0.70-1.5859
	All-cause mortality	0.41 (0.28-0.58)	0.50 (0.39-0.6 560
All patients	Intracranial hemorrhage	1.57 (0.80-3.07)	1.25 (0.77-2.04)1
	Gastrointestinal bleeding	0.86 (0.41-1.81)	562 1.04 (0.60-1.78) 563
	Ischemic stroke	0.89 (0.36-2.20)	1.28 (0.64-2.58) 564
Patients who did not receive heparin	All-cause mortality	0.52 (0.32-0.84)	0.59 (0.40-0.86) 565
within 14 days of fective endocarditis	Intracranial hemorrhage	2.54 (0.98-6.54)	2.56 (1.13-5.81)66
diagnosis	Gastrointestinal bleeding	1.67 (0.40-6.98)	0.90 (0.37-2.2 367
	Ischemic stroke	1.37 (0.76-2.48)	1.61 (1.00-2.65)8
Patients who did not receive cardiac	All-cause mortality	0.35 (0.22-0.54)	569 0.47 (0.35-0.64)
surgery within 14 days of infective	Intracranial hemorrhage	1.71 (0.78-3.73)	570 1.89 (1.01-3.53) 571
endocarditis diagnosis	Gastrointestinal bleeding	1.22 (0.51-2.95)	1.34 (0.73-2.47) 572

Table 2: Main and subgroup analyses of study outcomes 556

573 CI: Confidence interval. HR: Hazard ratio.

Table 3: Results of sensitivity analyses 574

Analysis done	Outcomes	30-day	90-day	575
	Ischemic stroke	0.64 (0.37-1.11) 1	0.81 (0.54-	1.2 576
Restricting to patients who had warfarin	All-cause mortality	0.48 (0.33-0.71) 1	0.51 (0.38-	-0.6 5 77
initiated within seven days of infective	Intracranial hemorrhage	1.00 (0.51-1.96) 1	0.75 (0.45-	,
endocarditis diagnosis	Gastrointestinal bleeding	0.52 (0.22-1.23) 1	0.56 (0.30-	579 -1.03) ¹ 580
Fine-Gray competing	Ischemic stroke	0.95 (0.55-1.65) ²	1.11 (0.74-	-1.68) ² 581
risk regression with all-cause mortality as	Intracranial hemorrhage	3.34 (1.34-8.31) ²	1.63 (0.95-	-2.81) ² 582
competing event	Gastrointestinal bleeding	0.99 (0.41-2.39) ²	1.14 (0.63-	-2.0 5 83
				584

¹ Hazard ratio and 95% confidence intervals 585

² Sub-hazard ratio and 95% confidence intervals 586


medRxiv preprint doi: https://doi.org/10.1101/2023.03.24.23287724; this version posted March 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. CC-BY-NC-ND 4.0 International license . It is made available under a

Figure 2: Kaplan-Meier curves of cumulative freedom from the study outcomes, 588

589 stratified by warfarin use. CI, confidence interval. HR, hazard ratio

590



592 Figure 3: Kaplan-Meier survival curves of study outcomes, stratified by the timing of

warfarin initiation. CI, confidence interval. HR, hazard ratio. 593

